Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Debt Repayment?

  Alexion Pharmaceuticals Inc ( ALXN ) |
2009 - 2021 (13 years)

Debt Repayment is 
$130.7M (1Y -38.4% )

ALXN Stock Price & Debt Repayment

Debt Repayment for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Debt Repayment

chevron_right 2021 $32.7M +0.4x
( +2.3% / year avg)
chevron_left 2009 $24.2M
vertical_align_top Peak $577.8M +27.1x
vertical_align_bottom Bottom $20.6M
arrow_drop_up # Up Years 6 6 of 13
years up.
arrow_drop_down # Down Years 7
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 2009 , or +112x faster than it's debt repayment over the same period.
  • If ALXN grows it's stock at the same rate as it's debt repayment (+2.3%/year) , it's stock price will grow +125% and hit $136.48 over the next 10 years.
  • ALXN's stock price has gone up 3 of the 6 years (+50%) it's debt repayment were also up.
  • ALXN Historical Debt Repayment Table
    in $ million
    Year Debt Repayment YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $32 -74.9% $108.72 -4.8%
    4/1/2020 $130 -76.9% $114.22 13.4%
    4/1/2019 $565 -2.1% $100.76 -17.6%
    4/1/2018 $577 69.4% $122.24 -14.2%
    4/1/2017 $341 -16.1% $142.41 -5.6%
    4/1/2016 $406 -1.9% $150.9 -7.9%
    4/1/2015 $414 646.2% $163.84 -1.5%
    4/1/2014 $55 18.8% $166.32 70.4%
    4/1/2013 $46 -76.0% $97.58 7.7%
    4/1/2012 $194 220.6% $90.57 91.0%
    4/1/2011 $60 195.5% $47.42 89.6%
    4/1/2010 $20 -15.1% $25.02 37.1%
    4/1/2009 $24 - $18.25 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • The repayment of debt.

    For more detailed definitions, please see Investopedia.